Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$50.11M, compared with -$31.53M a year earlier. Trailing-twelve-month EBITDA was -$29.53M.
Context
- EBITDA amounted to 7952.3% of revenue in FY2025, up 6596.1 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 11 analysts of -$132.82M (+18.0%) for the fiscal year ending Dec 2026, a step up from the -91.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$50.11M-22.9% QoQ
- Last fiscal yearDec 2025
- -$161.91M-91.5% YoY
- LTMJun 2026
- -$29.53M+74.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -58.9% | -47.4% | +11.5 pp |
| 1 year | -91.5% | +18.0% | +109.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (161.91M) USD
- Year-over-year change
- -91.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (161.91M) | -91.5% |
| FY2024 | 2024-12-31 | (84.56M) | -95.7% |
| FY2023 | 2023-12-31 | (43.2M) | -52.5% |
| FY2022 | 2022-12-31 | (28.33M) | -155.5% |
| FY2021 | 2021-12-31 | (11.09M) | — |
EBITDA vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 EBITDA of -$29.53M is the 3rd highest of the 10 companies compared; the peer median is -$158.55M.
- Its year-over-year change of +74.2% is the 3rd highest of 10, against a peer median of -35.4%.
- EBITDA amounts to 1550.9% of revenue for DNTH, versus a peer median of 6586.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $58.49M | +176.6% | — | 25.2% | |
| LTM Mar 2026 | $22.15M | +154.8% | — | 41.2% | |
| LTM Jun 2026 | -$29.53M | +74.2% | — | 1550.9% | |
| FY2025 | -$54.58M | -270.2% | — | 85279.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M | -35.4% | — | — |
| LTM Mar 2026 | -$158.55M | -341.7% | — | 8932.3% | |
| LTM Mar 2026 | -$245.81M | -69.1% | — | — | |
| LTM Jun 2026 | -$393.82M | -87.1% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$442.87M | -9.5% | — | 5986.3% |
| LTM Sep 2026 | -$509.88M | -10.4% | — | 7186.4% | |
| Peer median (excluding DNTH) | -$158.55M | -35.4% | — | 6586.3% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M |
| Selling, General & Admin | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M |
| Operating Expenses | 14.56M | 36.12M | 51M | 108.1M | 179.97M |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| EBITDA | (11.09M) | (28.33M) | (43.2M) | (84.56M) | (161.91M) |
| EBITDA Margin | -751.3% | -441.5% | -1528.7% | -1356.2% | -7952.3% |
| Operating Income | (13.09M) | (29.71M) | (48.17M) | (101.86M) | (177.93M) |
| Operating Margin | -886.6% | -462.9% | -1704.7% | -1633.7% | -8739.3% |
| Interest Income | 100K | 1.15M | 4.76M | 17.37M | 16.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (23K) | 1.23M | 4.62M | 16.9M | 15.6M |
| Income Before Tax | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Pre-Tax Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Net Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| EPS (Basic) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| EPS (Diluted) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| Weighted Avg Shares | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
| Weighted Avg Shares (Diluted) | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.